{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:18:47Z","timestamp":1783477127892,"version":"3.55.0"},"reference-count":201,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The gut microbiota is a pivotal actor in the maintenance of the balance in the complex interconnections of hepato-biliary-pancreatic system. It has both metabolic and immunologic functions, with an influence on the homeostasis of the whole organism and on the pathogenesis of a wide range of diseases, from non-neoplastic ones to tumorigenesis. The continuous bidirectional metabolic communication between gut and hepato-pancreatic district, through bile ducts and portal vein, leads to a continuous interaction with translocated bacteria and their products. Chronic liver disease and pancreatic disorders can lead to reduced intestinal motility, decreased bile acid synthesis and intestinal immune dysfunction, determining a compositional and functional imbalance in gut microbiota (dysbiosis), with potentially harmful consequences on the host\u2019s health. The modulation of the gut microbiota by antibiotics represents a pioneering challenge with striking future therapeutic opportunities, even in non-infectious diseases. In this setting, antibiotics are aimed at harmonizing gut microbial function and, sometimes, composition. A more targeted and specific approach should be the goal to pursue in the future, tailoring the treatment according to the type of microbiota modulation to be achieved and using combined strategies.<\/jats:p>","DOI":"10.3390\/antibiotics12061068","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T01:31:14Z","timestamp":1687138274000},"page":"1068","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-7641","authenticated-orcid":false,"given":"Federica","family":"Di Vincenzo","sequence":"first","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7734-0538","authenticated-orcid":false,"given":"Marcantonio","family":"Negri","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Vitale","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Zileri Dal Verme","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6230-1779","authenticated-orcid":false,"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-7582","authenticated-orcid":false,"given":"Lucia","family":"Cerrito","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"ref_1","first-page":"284680","article-title":"Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies","volume":"2015","author":"Velloso","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/jgh.12294","article-title":"Role of the gut microbiota in human nutrition and metabolism: Role of the Gut Microbiota","volume":"28","author":"Ramakrishna","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/gutjnl-2019-320490","article-title":"Liver tissue microbiome in NAFLD: Next step in understanding the gut\u2013liver axis?","volume":"69","author":"Tilg","year":"2020","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases","volume":"26","author":"An","year":"2022","journal-title":"J. Gastrointest. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tuomisto, S., Pessi, T., Collin, P., Vuento, R., Aittoniemi, J., and Karhunen, P.J. (2014). Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol., 14.","DOI":"10.1186\/1471-230X-14-40"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00248-010-9801-8","article-title":"Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection: Intestinal Microbiota of HBV Cirrhotic Patients","volume":"61","author":"Lu","year":"2011","journal-title":"Microb. Ecol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wei, X., Yan, X., Zou, D., Yang, Z., Wang, X., Liu, W., Wang, S., Li, X., Han, J., and Huang, L. (2013). Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol., 13.","DOI":"10.1186\/1471-230X-13-175"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/ajg.2013.221","article-title":"Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing","volume":"108","author":"Zhang","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/hep.27819","article-title":"Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy","volume":"62","author":"Bajaj","year":"2015","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/00365520150218110","article-title":"Small Intestinal Bacterial Overgrowth versus Antimicrobial Capacity in Patients with Spontaneous Bacterial Peritonitis","volume":"36","author":"Chang","year":"2001","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/gutjnl-2020-321663","article-title":"Novel pathomechanism for spontaneous bacterial peritonitis: Disruption of cell junctions by cellular and bacterial proteases","volume":"71","author":"Haderer","year":"2022","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.cgh.2015.06.039","article-title":"Covert and Overt Hepatic Encephalopathy: Diagnosis and Management","volume":"13","author":"Patidar","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cld.2020.01.012","article-title":"Minimal Hepatic Encephalopathy","volume":"24","author":"Karanfilian","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cld.2020.01.001","article-title":"Epidemiology of Hepatic Encephalopathy","volume":"24","author":"Elsaid","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ajg.2015.377","article-title":"Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study","volume":"111","author":"Allampati","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2013.10.004","article-title":"Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF)","volume":"60","author":"Cordoba","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0037-1608832","article-title":"Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease","volume":"37","author":"Shah","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2010.05.017","article-title":"Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy","volume":"53","author":"Gupta","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yokoyama, K., Sakamaki, A., Takahashi, K., Naruse, T., Sato, C., Kawata, Y., Tominaga, K., Abe, H., Sato, H., and Tsuchiya, A. (2022). Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264459"},{"key":"ref_26","first-page":"G168","article-title":"Linkage of gut microbiome with cognition in hepatic encephalopathy","volume":"302","author":"Bajaj","year":"2012","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_27","first-page":"G675","article-title":"Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation","volume":"303","author":"Bajaj","year":"2012","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2022.2111300","article-title":"Altered gut microbiota is associated with sleep disturbances in patients with minimal hepatic encephalopathy caused by hepatitis B-related liver cirrhosis","volume":"16","author":"Luo","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.30690","article-title":"Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial","volume":"70","author":"Bajaj","year":"2019","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.aaq0926","article-title":"Gut microbiota utilize immunoglobulin A for mucosal colonization","volume":"360","author":"Donaldson","year":"2018","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.aninu.2020.09.002","article-title":"Interplay between gut microbiota and antimicrobial peptides","volume":"6","author":"Zong","year":"2020","journal-title":"Anim. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4161\/gmic.24706","article-title":"Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host","volume":"4","author":"Alaish","year":"2013","journal-title":"Gut Microbes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fimmu.2014.00221","article-title":"Role of Toll-Like Receptors in Immune Activation and Tolerance in the Liver","volume":"5","author":"Nakamoto","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.12.002","article-title":"Gut\u2013liver immunity","volume":"64","author":"Trivedi","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1038\/s41598-017-05938-1","article-title":"Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28\u2212, Th22 and Tfh and B lymphocytes","volume":"7","author":"Urios","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11011-006-9042-1","article-title":"Role of ammonia and inflammation in minimal hepatic encephalopathy","volume":"22","author":"Shawcross","year":"2007","journal-title":"Metab. Brain Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fcimb.2020.00022","article-title":"Gastrointestinal (GI) Tract Microbiome-Derived Neurotoxins\u2014Potent Neuro-Inflammatory Signals From the GI Tract via the Systemic Circulation Into the Brain","volume":"10","author":"Lukiw","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","article-title":"The blood\u2013brain barrier in systemic infection and inflammation","volume":"18","author":"Galea","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrgastro.2013.99","article-title":"The liver\u2013brain axis in liver failure: Neuroinflammation and encephalopathy","volume":"10","author":"Butterworth","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jhep.2019.01.008","article-title":"Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: Reversed by anti-TNF-\u03b1 treatment","volume":"73","author":"Balzano","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.28696","article-title":"Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice","volume":"64","author":"Kang","year":"2016","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/hep.30827","article-title":"Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2958.1993.tb01220.x","article-title":"Bacterial ureases: Structure, regulation of expression and role in pathogenesis","volume":"9","author":"Collins","year":"1993","journal-title":"Mol. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"134818","DOI":"10.1016\/j.neulet.2020.134818","article-title":"Cerebral edema and liver disease: Classic perspectives and contemporary hypotheses on mechanism","volume":"721","author":"Liotta","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.neuint.2005.11.017","article-title":"Glutamine in the mechanism of ammonia-induced astrocyte swelling","volume":"48","author":"Jayakumar","year":"2006","journal-title":"Neurochem. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1053\/j.gastro.2010.03.040","article-title":"Hyperammonemia Induces Neuroinflammation That Contributes to Cognitive Impairment in Rats With Hepatic Encephalopathy","volume":"139","author":"Rodrigo","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12974-016-0505-y","article-title":"Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: Reversal by sulforaphane","volume":"13","author":"Malaguarnera","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bajaj, J.S., Heuman, D.M., Sanyal, A.J., Hylemon, P.B., Sterling, R.K., Stravitz, R.T., Fuchs, M., Ridlon, J.M., Daita, K., and Monteith, P. (2013). Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060042"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/liv.12021","article-title":"Pathological bacterial translocation in cirrhosis: Pathophysiology, diagnosis and clinical implications","volume":"33","author":"Bellot","year":"2012","journal-title":"Liver Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbi.2008.09.002","article-title":"Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1\u03b2 and anti-inflammatory IL-10 cytokines","volume":"23","author":"Henry","year":"2009","journal-title":"Brain, Behav. Immun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/gutjnl-2014-308419","article-title":"Intestinal deletion of Claudin-7 enhances paracellular organic solute flux and initiates colonic inflammation in mice","volume":"64","author":"Tanaka","year":"2015","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.21599","article-title":"Endotoxemia produces coma and brain swelling in bile duct ligated rats","volume":"45","author":"Wright","year":"2007","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/1751-2980.12816","article-title":"Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial","volume":"20","author":"Wang","year":"2019","journal-title":"J. Dig. Dis."},{"key":"ref_54","unstructured":"(2007). Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd."},{"key":"ref_55","first-page":"292","article-title":"Kanakasabapathy, null Effect of Three Antibacterial Drugs in Lowering Blood & Stool Ammonia Production in Hepatic Encephalopathy","volume":"96","author":"Alexander","year":"1992","journal-title":"Indian J. Med. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1136\/gut.31.12.1424-b","article-title":"Vancomycin in resistant hepatic encephalopathy","volume":"31","author":"Forbes","year":"1990","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jhbp.947","article-title":"Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial","volume":"28","author":"Glal","year":"2021","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jceh.2022.01.012","article-title":"Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel","volume":"12","author":"Rajpurohit","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","article-title":"Eubiotic Properties of Rifaximin: Disruption of the Traditional Concepts in Gut Microbiota Modulation","volume":"23","author":"Ponziani","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin Treatment in Hepatic Encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3748\/wjg.v18.i8.767","article-title":"Rifaximin vs. conventional oral therapy for hepatic encephalopathy: A meta-analysis","volume":"18","author":"Eltawil","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","article-title":"Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial","volume":"76","author":"Patel","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_64","first-page":"4887","article-title":"Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients","volume":"14","author":"Zuo","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Review article: Potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis","volume":"43","author":"Bajaj","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8355","DOI":"10.3748\/wjg.v23.i47.8355","article-title":"Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity","volume":"23","author":"Kaji","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kaji, K., Saikawa, S., Takaya, H., Fujinaga, Y., Furukawa, M., Kitagawa, K., Ozutsumi, T., Kaya, D., Tsuji, Y., and Sawada, Y. (2020). Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. Antibiotics, 9.","DOI":"10.3390\/antibiotics9040145"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000494216","article-title":"Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy","volume":"37","author":"Schulz","year":"2019","journal-title":"Dig. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/19490976.2017.1290757","article-title":"Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease","volume":"8","author":"Weingarden","year":"2017","journal-title":"Gut Microbes"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"key":"ref_71","first-page":"e133410","article-title":"Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis","volume":"4","author":"Bajaj","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/00365521.2021.1899277","article-title":"Fecal microbiota transplantation in hepatic encephalopathy: A systematic review","volume":"56","author":"Madsen","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hep4.1639","article-title":"Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials","volume":"5","author":"Bajaj","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/HMER.S164250","article-title":"Spontaneous bacterial peritonitis in patients with cirrhosis: Incidence, outcomes, and treatment strategies","volume":"11","author":"Marciano","year":"2019","journal-title":"Hepatic Med. \u00c9vid. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hep.1840160318","article-title":"Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration","volume":"16","author":"Llach","year":"1992","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ajg.2009.3","article-title":"Oral Antibiotic Prophylaxis Reduces Spontaneous Bacterial Peritonitis Occurrence and Improves Short-Term Survival in Cirrhosis: A Meta-Analysis","volume":"104","author":"Saab","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jhep.2011.02.022","article-title":"Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis","volume":"55","author":"Nischalke","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10096-010-0891-5","article-title":"Characterisation of bacteria in ascites\u2014Reporting the potential of culture-independent, molecular analysis","volume":"29","author":"Rogers","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Rogers, G.B., Van Der Gast, C.J., Bruce, K.D., Marsh, P., Collins, J.E., Sutton, J., and Wright, M. (2013). Ascitic Microbiota Composition Is Correlated with Clinical Severity in Cirrhosis with Portal Hypertension. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074884"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.1840120416","article-title":"Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial","volume":"12","author":"Rimola","year":"1990","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2036.2011.04746.x","article-title":"Meta-analysis: Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding\u2014An updated Cochrane review: Meta-Analysis: Antibiotics and Cirrhotic Gastrointestinal Bleeding","volume":"34","author":"Gluud","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/hep.22853","article-title":"Management of adult patients with ascites due to cirrhosis: An update","volume":"49","author":"Runyon","year":"2009","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"999418","DOI":"10.3389\/fcimb.2022.999418","article-title":"Alterations of gut microbiota in cirrhotic patients with spontaneous bacterial peritonitis: A distinctive diagnostic feature","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/hep.28330","article-title":"Antibiotic prophylaxis in cirrhosis: Good and bad","volume":"63","author":"Tandon","year":"2016","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3748\/wjg.v18.i14.1700","article-title":"Rifaximin for the prevention of spontaneous bacterial peritonitis","volume":"18","author":"Kalambokis","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_89","first-page":"315","article-title":"The role of rifaximine in the prevention of the spontaneous bacterial peritonitis","volume":"117","author":"Stanciu","year":"2013","journal-title":"Rev. Med.-Chir."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MCG.0b013e3182506dbb","article-title":"The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis","volume":"46","author":"Hanouneh","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5152\/tjg.2015.7782","article-title":"The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients","volume":"26","author":"Mostafa","year":"2015","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e000154","DOI":"10.1136\/bmjgast-2017-000154","article-title":"Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: A systematic review","volume":"4","author":"Sidhu","year":"2017","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/apt.14361","article-title":"Systematic review with meta-analysis: Rifaximin for the prophylaxis of spontaneous bacterial peritonitis","volume":"46","author":"Goel","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4254\/wjh.v12.i5.239","article-title":"Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis","volume":"12","author":"Faust","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2174\/1389450119666180924145156","article-title":"Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis","volume":"20","author":"Menshawy","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12072-015-9688-z","article-title":"Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: A prospective randomized open-label comparative multicenter study","volume":"10","author":"Assem","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"g4859","DOI":"10.1136\/bmj.g4859","article-title":"Acute pancreatitis","volume":"349","author":"Johnson","year":"2014","journal-title":"BMJ"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pan.2017.01.005","article-title":"The incidence and aetiology of acute pancreatitis across Europe","volume":"17","author":"Roberts","year":"2017","journal-title":"Pancreatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20142012: Revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/00003246-199510000-00007","article-title":"Multiple Organ Dysfunction Score: A Reliable Descriptor of a Complex Clinical Outcome","volume":"23","author":"Marshall","year":"1995","journal-title":"Crit. Care Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000243731","article-title":"Practice and Yield of Early CT Scan in Acute Pancreatitis: A Dutch Observational Multicenter Study","volume":"10","author":"Spanier","year":"2010","journal-title":"Pancreatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1148\/radiology.174.2.2296641","article-title":"Acute pancreatitis: Value of CT in establishing prognosis","volume":"174","author":"Balthazar","year":"1990","journal-title":"Radiology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.pan.2016.07.004","article-title":"Infection increases mortality in necrotizing pancreatitis: A systematic review and meta-analysis","volume":"16","author":"Werge","year":"2016","journal-title":"Pancreatology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/SLA.0000000000000264","article-title":"The Role of Organ Failure and Infection in Necrotizing Pancreatitis","volume":"259","author":"Guo","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1053\/j.gastro.2010.06.010","article-title":"Organ Failure and Infection of Pancreatic Necrosis as Determinants of Mortality in Patients With Acute Pancreatitis","volume":"139","author":"Petrov","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"686","DOI":"10.5009\/gnl210362","article-title":"The Role of Gut Microbiota and Genetic Susceptibility in the Pathogenesis of Pancreatitis","volume":"16","author":"Xu","year":"2022","journal-title":"Gut Liver"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1053\/j.gastro.2012.12.043","article-title":"Models of Acute and Chronic Pancreatitis","volume":"144","author":"Lerch","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_108","first-page":"81","article-title":"Intestinal Microbial Community Differs between Acute Pancreatitis Patients and Healthy Volunteers","volume":"31","author":"Zhang","year":"2018","journal-title":"Biomed. Environ. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/CCM.0b013e31828a3dba","article-title":"Bacteremia in Patients With Acute Pancreatitis as Revealed by 16S Ribosomal RNA Gene-Based Techniques*","volume":"41","author":"Li","year":"2013","journal-title":"Crit. Care Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s10620-020-06061-4","article-title":"Identification of Dysfunctional Gut Microbiota Through Rectal Swab in Patients with Different Severity of Acute Pancreatitis","volume":"65","author":"Yu","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00535-018-1529-0","article-title":"Gut microbiota dysbiosis worsens the severity of acute pancreatitis in patients and mice","volume":"54","author":"Zhu","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40168-021-01065-2","article-title":"Parabacteroides produces acetate to alleviate heparanase-exacerbated acute pancreatitis through reducing neutrophil infiltration","volume":"9","author":"Lei","year":"2021","journal-title":"Microbiome"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.pan.2019.04.003","article-title":"Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations","volume":"19","author":"Lantos","year":"2019","journal-title":"Pancreatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.pan.2013.07.063","article-title":"IAP\/APA evidence-based guidelines for the management of acute pancreatitis","volume":"13","author":"Deviere","year":"2013","journal-title":"Pancreatology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0031-1275529","article-title":"Rational Use of Antimicrobials in Patients with Severe Acute Pancreatitis","volume":"32","year":"2011","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/ajg.2013.218","article-title":"American College of Gastroenterology Guideline: Management of Acute Pancreatitis","volume":"108","author":"Tenner","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/TA.0000000000003502","article-title":"Prognostic factors associated with development of infected necrosis in patients with acute necrotizing or severe pancreatitis\u2014A systematic review and meta-analysis","volume":"92","author":"Tran","year":"2022","journal-title":"J. Trauma: Inj. Infect. Crit. Care"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"101901","DOI":"10.1016\/j.clinre.2022.101901","article-title":"Risk factors for concomitant infectious pancreatic necrosis in patients with severe acute pancreatitis: A systematic review and meta-analysis","volume":"46","author":"Li","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.pan.2018.05.485","article-title":"Mis-use of antibiotics in acute pancreatitis: Insights from the United Kingdom\u2019s National Confidential Enquiry into patient outcome and death (NCEPOD) survey of acute pancreatitis","volume":"18","author":"Barrie","year":"2018","journal-title":"Pancreatology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.pan.2016.08.012","article-title":"Antibiotic use in acute pancreatitis: An audit of current practice in a tertiary centre","volume":"16","author":"Baltatzis","year":"2016","journal-title":"Pancreatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2468-1253(22)00212-6","article-title":"A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): A single-centre, patient-blinded, randomised controlled trial","volume":"7","author":"Siriwardena","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MPA.0000000000000965","article-title":"Fungal Infections in Patients With Infected Pancreatic Necrosis and Pseudocysts","volume":"47","author":"Reuken","year":"2018","journal-title":"Pancreas"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/0016-5085(92)91450-I","article-title":"Human pancreatic tissue concentration of bactericidal antibiotics","volume":"103","author":"Malfertheiner","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13651820500467275","article-title":"Efficacy of antibiotic penetration into pancreatic necrosis","volume":"8","author":"Otto","year":"2006","journal-title":"HPB"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1128\/AAC.00872-12","article-title":"Activity of Moxifloxacin, Imipenem, and Ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in Monocultures and Mixed Cultures in an In Vitro Pharmacokinetic\/Pharmacodynamic Model Simulating Concentrations in the Human Pancreas","volume":"56","author":"Schubert","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13017-019-0247-0","article-title":"2019 WSES guidelines for the management of severe acute pancreatitis","volume":"14","author":"Tolonen","year":"2019","journal-title":"World J. Emerg. Surg."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2100826","article-title":"Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis","volume":"385","author":"Boxhoorn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000084485","article-title":"Antibiotic prophylaxis in severe acute pancreatitis","volume":"5","author":"Beger","year":"2005","journal-title":"Pancreatology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/00365521.2010.531486","article-title":"Systematic review and meta-analysis of antibiotic prophylaxis in severe acute pancreatitis","volume":"46","author":"Wittau","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11605-014-2662-6","article-title":"Role of Antibiotic Prophylaxis in Necrotizing Pancreatitis: A Meta-Analysis","volume":"19","author":"Lim","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000520892","article-title":"Assessment of Prophylactic Carbapenem Antibiotics Administration for Severe Acute Pancreatitis: An Updated Systematic Review and Meta-Analysis","volume":"103","author":"Guo","year":"2022","journal-title":"Digestion"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jiac.2018.05.009","article-title":"Early prophylactic antibiotics for severe acute pancreatitis: A population-based cohort study using a nationwide database in Japan","volume":"24","author":"Nakaharai","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1053\/j.gastro.2018.01.032","article-title":"American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis","volume":"154","author":"Crockett","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pan.2015.12.179","article-title":"Antibiotic use in acute pancreatitis: Global overview of compliance with international guidelines","volume":"16","author":"Baltatzis","year":"2016","journal-title":"Pancreatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1365-2168.1999.01052.x","article-title":"Survey of antibiotic prophylaxis in acute pancreatitis in the UK and Ireland","volume":"86","author":"Powell","year":"1999","journal-title":"Br. J. Surg."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1572-0241.2004.04111.x","article-title":"European Survey of Surgical Strategies for the Management of Severe Acute Pancreatitis","volume":"99","author":"King","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_137","first-page":"221","article-title":"Poor Compliance with ACG Guidelines for Nutrition and Antibiotics in the Management of Acute Pancreatitis: A North American Survey of Gastrointestinal Specialists and Primary Care Physicians","volume":"14","author":"Sun","year":"2013","journal-title":"JOP J. Pancreas"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00534-009-0212-5","article-title":"Changes in management of acute pancreatitis before and after the publication of evidence-based practice guidelines in 2003","volume":"17","author":"Sekimoto","year":"2010","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.hbpd.2018.08.007","article-title":"The microbiology of infected pancreatic necrosis","volume":"17","author":"Mowbray","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/j.gastro.2018.01.031","article-title":"Initial Medical Treatment of Acute Pancreatitis: American Gastroenterological Association Institute Technical Review","volume":"154","author":"Vege","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(08)60207-X","article-title":"Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial","volume":"371","author":"Besselink","year":"2008","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg. Infect."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jhbp.509","article-title":"Tokyo Guidelines 2018: Initial management of acute biliary infection and flowchart for acute cholangitis","volume":"25","author":"Miura","year":"2018","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.dld.2021.04.028","article-title":"Treatment of primary sclerosing cholangitis","volume":"53","author":"Floreani","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/flgastro-2019-101343","article-title":"Guideline review: British Society of Gastroenterology\/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"12","author":"Nicoletti","year":"2021","journal-title":"Front. Gastroenterol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.gie.2015.01.021","article-title":"Antibiotic prophylaxis for GI endoscopy","volume":"81","author":"Tang","year":"2015","journal-title":"Gastrointest. Endosc."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/clinids\/20.5.1236","article-title":"Antibiotic Prophylaxis for Infectious Complications after Therapeutic Endoscopic Retrograde Cholangiopancreatography: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"20","author":"Byl","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ajg.2008.161","article-title":"Complications of Endoscopic Retrograde Cholangiopancreatography in Primary Sclerosing Cholangitis","volume":"104","author":"Bangarulingam","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.3748\/wjg.v25.i33.4814","article-title":"Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation","volume":"25","author":"Nicoletti","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut\u2013liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41564-019-0483-9","article-title":"Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC\/IBD diagnoses","volume":"4","author":"Sabino","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_154","first-page":"2750","article-title":"Biliary Tract Microbiota: A New Kid on the Block of Liver Diseases?","volume":"24","author":"Nicoletti","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gutjnl-2019-318416","article-title":"Alterations of the bile microbiome in primary sclerosing cholangitis","volume":"69","author":"Liwinski","year":"2020","journal-title":"Gut"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Pereira, P., Aho, V., Arola, J., Boyd, S., Jokelainen, K., Paulin, L., Auvinen, P., and F\u00e4rkkil\u00e4, M. (2017). Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182924"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial","volume":"40","author":"Karvonen","year":"2004","journal-title":"Hepatology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014A pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: A Pilot Study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: Oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"Ali","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","article-title":"Long-term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating Antibiotic","volume":"47","author":"Davies","year":"2008","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: Pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MOG.0000000000000708","article-title":"Primary biliary cholangitis: Treatment","volume":"37","author":"Cazzagon","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2009). European Association for the Stud EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J. Hepatol., 51, 237\u2013267.","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cei.13198","article-title":"Pathogen infections and primary biliary cholangitis","volume":"195","author":"Tanaka","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12016-008-8087-9","article-title":"Bacteria and Primary Biliary Cirrhosis","volume":"36","author":"Bogdanos","year":"2009","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1034\/j.1600-0528.2002.017402.x","article-title":"Primary biliary cirrhosis: An orchestrated immune response against epithelial cells","volume":"174","author":"Gershwin","year":"2000","journal-title":"Immunol. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199611213352107","article-title":"Primary Biliary Cirrhosis","volume":"335","author":"Kaplan","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/jhep.2003.50446","article-title":"Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium","volume":"38","author":"Selmi","year":"2003","journal-title":"Hepatology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0168-8278(05)80225-9","article-title":"M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria","volume":"17","author":"Butler","year":"1993","journal-title":"J. Hepatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1155\/2010\/595078","article-title":"The Role of E. coli Infection in the Pathogenesis of Primary Biliary Cirrhosis","volume":"29","author":"Bogdanos","year":"2010","journal-title":"Dis. Markers"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.3748\/wjg.v18.i35.4855","article-title":"Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?","volume":"18","author":"Smyk","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2003.11.033","article-title":"Primary biliary cirrhosis: An infectious disease caused by Chlamydia pneumoniae?","volume":"40","author":"Abdulkarim","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_180","first-page":"13","article-title":"Chronic Atrophic Gastritis and Helicobacter Pylori Infection in Primary Biliary Cirrhosis: A Cross-Sectional Study with Match-ing","volume":"29","author":"Floreani","year":"1997","journal-title":"Ital. J. Gastroenterol. Hepatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.yexmp.2012.09.012","article-title":"Serum markers of infections in patients with primary biliary cirrhosis: Evidence of infection burden","volume":"93","author":"Shapira","year":"2012","journal-title":"Exp. Mol. Pathol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/1462-2920.13401","article-title":"Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis","volume":"18","author":"Lv","year":"2016","journal-title":"Environ. Microbiol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","article-title":"Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis","volume":"58","author":"Chen","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014A comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Carstens, E., and Akiyama, T. (2014). Itch: Mechanisms and Treatment, Taylor & Francis. Frontiers in Neuroscience.","DOI":"10.1201\/b16573"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","article-title":"Interaction between drugs and the gut microbiome","volume":"69","author":"Weersma","year":"2020","journal-title":"Gut"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000443360","article-title":"Effects of Antibiotics on Gut Microbiota","volume":"34","author":"Lange","year":"2016","journal-title":"Dig. Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/19490976.2015.1062959","article-title":"Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin","volume":"6","author":"Heinsen","year":"2015","journal-title":"Gut Microbes"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"572912","DOI":"10.3389\/fcimb.2020.572912","article-title":"Antibiotics as Major Disruptors of Gut Microbiota","volume":"10","author":"Ramirez","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e00007-19","DOI":"10.1128\/MMBR.00007-19","article-title":"Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection","volume":"83","author":"Ducarmon","year":"2019","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"164","DOI":"10.15252\/embr.201439263","article-title":"The composition of the gut microbiota shapes the colon mucus barrier","volume":"16","author":"Jakobsson","year":"2015","journal-title":"EMBO Rep."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gutjnl-2020-321829","article-title":"Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic","volume":"69","author":"Ianiro","year":"2020","journal-title":"Gut"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nri3535","article-title":"Microbiota-mediated colonization resistance against intestinal pathogens","volume":"13","author":"Buffie","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1099\/jmm.0.000972","article-title":"Integrons and antibiotic resistance genes in water-borne pathogens: Threat detection and risk assessment","volume":"68","author":"Kaushik","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1073\/pnas.1120238109","article-title":"In-feed antibiotic effects on the swine intestinal microbiome","volume":"109","author":"Looft","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/ismej.2014.12","article-title":"Bacteria, phages and pigs: The effects of in-feed antibiotics on the microbiome at different gut locations","volume":"8","author":"Looft","year":"2014","journal-title":"ISME J."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.1223813","article-title":"Host-Gut Microbiota Metabolic Interactions","volume":"336","author":"Nicholson","year":"2012","journal-title":"Science"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"ofv078","DOI":"10.1093\/ofid\/ofv078","article-title":"Loss of Vancomycin-Resistant Enterococcus Fecal Dominance in an Organ Transplant Patient With Clostridium difficile Colitis After Fecal Microbiota Transplant","volume":"2","author":"Stripling","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fcimb.2019.00454","article-title":"How Probiotics Affect the Microbiota","volume":"9","author":"Belkhir","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Shi, Y., Luo, J., Narbad, A., and Chen, Q. (2023). Advances in Lactobacillus Restoration for \u03b2-Lactam Antibiotic-Induced Dysbiosis: A System Review in Intestinal Microbiota and Immune Homeostasis. Microorganisms, 11.","DOI":"10.3390\/microorganisms11010179"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Satokari, R. (2019). Modulation of Gut Microbiota for Health by Current and Next-Generation Probiotics. Nutrients, 11.","DOI":"10.3390\/nu11081921"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/1068\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:55:33Z","timestamp":1760126133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/1068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":201,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antibiotics12061068"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12061068","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]}}}